← Back to Search

Catheter Ablation

Mapping and Ablation for Atrial Fibrillation (SPHERE Per-AF Trial)

N/A
Waitlist Available
Research Sponsored by Affera, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

SPHERE Per-AF Trial Summary

This trial is testing a new mapping and ablation catheter against a control device to see if the investigational device is more effective.

Who is the study for?
Adults aged 18-80 with persistent atrial fibrillation (AF) lasting more than 7 days but less than a year, who've had symptoms and failed or can't tolerate certain anti-arrhythmic drugs. They must be able to follow the study's procedures and give informed consent. Excluded are those with severe heart conditions, recent strokes or surgeries, pregnant women, and individuals with other major health issues.Check my eligibility
What is being tested?
The trial is testing two different catheter ablation tools for treating AF: the investigational Sphere-9 Catheter with Affera System versus the control THERMOCOOL SMARTTOUCH® SF catheter. Participants will be randomly assigned in equal numbers to either treatment group.See study design
What are the potential side effects?
Possible side effects from catheter ablation may include discomfort at the access site, bleeding, heart rhythm problems, blood vessel complications, and rarely more serious heart or lung issues.

SPHERE Per-AF Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percent of subjects free from primary effectiveness failure
Percent of subjects with a primary adverse event
Secondary outcome measures
Energy application time
Procedure time
Treatment time

SPHERE Per-AF Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Sphere-9 CatheterExperimental Treatment1 Intervention
Sphere-9™ Mapping and Ablation Catheter; Affera Mapping System; Affera Ablation System
Group II: THERMOCOOL SMARTTOUCH SFActive Control1 Intervention
THERMOCOOL SMARTTOUCH® SF Catheter; SMARTABLATE® System; CARTO® 3 System
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mapping and Ablation
2021
N/A
~480

Find a Location

Who is running the clinical trial?

Affera, Inc.Lead Sponsor
2 Previous Clinical Trials
100 Total Patients Enrolled
2 Trials studying Atrial Fibrillation
100 Patients Enrolled for Atrial Fibrillation

Media Library

Sphere-9 Mapping and Ablation Catheter (Catheter Ablation) Clinical Trial Eligibility Overview. Trial Name: NCT05120193 — N/A
Atrial Fibrillation Research Study Groups: Sphere-9 Catheter, THERMOCOOL SMARTTOUCH SF
Atrial Fibrillation Clinical Trial 2023: Sphere-9 Mapping and Ablation Catheter Highlights & Side Effects. Trial Name: NCT05120193 — N/A
Sphere-9 Mapping and Ablation Catheter (Catheter Ablation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05120193 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the age cut-off for this trial below sixty years old?

"The age range for enrolment in this study is 18 to 80, as per the eligibility requirements."

Answered by AI

What characteristics make individuals suitable candidates for this medical research?

"Candidates that meet the criteria of being between 18 and 80 years old, with a diagnosis of atrial fibrillation, may qualify for this medical trial. This study is currently seeking to enroll approximately 477 patients."

Answered by AI

What is the geographic range of this trial's implementation?

"Currently, 19 medical centres are enrolling patients for this trial. These sites span from Wormleysburg to Phoenix to New york and beyond. To reduce travel time associated with participation, we recommend selecting the closest site possible."

Answered by AI

Is this research actively recruiting participants?

"As reported on clinicaltrials.gov, the initial posting of this medical trial was on December 14th 2021 but is no longer actively recruiting candidates. However, there are still 476 other trials that require additional participants at present."

Answered by AI

Who else is applying?

What state do they live in?
Florida
How old are they?
18 - 65
What site did they apply to?
AdventHealth Orlando
What portion of applicants met pre-screening criteria?
Met criteria
~140 spots leftby May 2025